Andrew Eugene Hendifar

机构：Cedars-Sinai Medical Center · ORCID：0000-0002-2079-9177

发表论文 467 篇 · 总被引 14742 次 · h-index 53

代表论文

• Ponsegromab for the Treatment of Cancer Cachexia (2024 · New England Journal of Medicine · 被引 304)
• Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial (2025 · Nature Cancer · 被引 38)
• Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. (2026 · Journal of Clinical Oncology · 被引 11)
• ctDNA-guided adjuvant immunotherapy in colorectal cancer (2024 · Immunotherapy · 被引 9)
• Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma (2025 · Frontiers in Immunology · 被引 8)
• Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database (2025 · The Oncologist · 被引 7)